ClinicalTrials.gg
Status unknownNCT03489616CRAGMOLCUpdated Apr 5, 2018

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients

An interventional study of rhGM-CSF and Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Shandong Cancer Hospital and Institute. Status unknown at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-04-05.

Sponsored by Shandong Cancer Hospital and Institute · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies in Carcinoma, Non-Small-Cell Lung by Shandong Cancer Hospital and Institute — 1 open to participants now, 2 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Shandong Cancer Hospital and Institute.

Planned enrollment
5th of 15
45 · median 42
Started
2018
with 3 others
No phase
2 of 15
none open now
Registered
6th of 15
by date

Among the 15 studies in Carcinoma, Non-Small-Cell Lung by Shandong Cancer Hospital and Institute, this one is the 5th largest by planned enrollment, is one of 4 that started in 2018, is one of 2 with no phase, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 15 studies in Carcinoma, Non-Small-Cell Lung by Shandong Cancer Hospital and Institute is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Carcinoma, Non-Small-Cell Lung by Shandong Cancer Hospital and Institute, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether chemotherapy combination with local radiotherapy and rhGM-CSF is safe, effective in the treatment of oligometastatic stage IV NSCLC patients.

Read the detailed description

The purpose of this study is to determine whether chemotherapy combination with local radiotherapy and recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment of oligometastatic stage IV NSCLC patients who were PR or SD after first-line chemotherapy,and to observe the abscopal effect, whether the scheme can improve PFS and OS.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Stage IV NSCLC patients without clear driving genes who were PR or SD after standard chemotherapy;
  2. Patients who were oligometastasis evaluated by PET-CT or other examinations after first-line chemotherapy. Eligible patients should have 2 to 5 distant (at least 2 metastases were suitable for low fractionated radiotherapy). At least one distant outside the radiation sites.
  3. Age varied from 18 to 75 years old.
  4. performance status 0-2.
  5. Expected lifespan ≥3 months.
  6. (ANC) ≥1.5×109/L, ≥100×109/L, ≥90 g/L.
  7. Able to understand and give written and comply with study procedures.

Exclusion criteria

Exclusion criteria

  1. Allergy of rhGM-CSF and its accessories.
  2. Disease of systemic immune or immune disorders.
  3. Histology confirmed small cell carcinoma or other malignant compositions in the cancer tissue.
  4. Patients with thrombotic disease or ≥600×109/L
  5. Cancer history within 5 years apart from NSCLC before enrollment.
  6. Tumor related immunotherapy within 4 weeks, including but not limited to immune cell therapy, tumor vaccine therapy, Immune checkpoint therapy, and other immunomodulators (such as thymosin, lentinan) except for rhGM-CSF.
  7. The abnormality of kidney , heart or lung functions(serum creatinine, Cr>177mol/L; serum or ALT more than 2 times above normal limits; total , TBIL>34mol/L).
  8. virus, virus or T lymphocyte virus (type1 or type 2) infection and active hepatitis or other uncontrolled infections.
  9. Women in pregnancy or lactation.
  10. Others who do not meet the inclusion criteria.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Radiotherapy+chemotherapy+ rhGM-CSF

    Patients with PR or SD after first-line chemotherapy will be treated with pemetrexed on d1 (500mg/m2) or other single agent on d1, d8. Local radiotherapy dose will be\> 4Gy per time(or BED \>45Gy) from day 2 to day 15 in a cycle of 21 days. Subcutaneous injection of rhGM-CSF (200ug/m² per day) will be executed 24 hours after chemotherapy. Repeat in the second metastatic lesions.

    Biological: rhGM-CSF · Drug: Pemetrexed · Radiation: Local Radiotherapy · Drug: Single agent

  • Experimental
    Single agent maintenance therapy

    Maintenance treatment by single agent in a cycle of 21 days.

    Drug: Single agent

Interventions

  • BiologicalRegramostimStudies of RegramostimRegramostim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.

    Also known as: Recombinant human granulocyte macrophage stimulating factor

  • Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.

  • RadiationLocal Radiotherapy

    Radiotherapy promotes the release of tumor antigen

    Also known as: Local Radiation therapy

  • DrugSingle agent

    Other chemotherapy drugs,such as Docetaxel, gemcitabine

    Also known as: Single agent for maintenance therapy

06

What researchers measure

Primary outcomes

  1. PFS

    Progression-Free-Survival

    Time frame: 2 years

Secondary outcomes

  1. Abscopal effect rate

    Radiotherapy-induced immune-mediated tumour regression at sites distant to the irradiated field

    Time frame: At the time point of 4 weeks after completion of rhGM-CSF

  2. OS

    Overall survival

    Time frame: 2 years

07

Study locations

2 of 2 sites recruiting
  • Shandong Cancer Hospital and Institute
    Jinan, Shandong 250000, China
    Recruiting
  • SHANDONG Cancer Hospital
    Jinan, Shandong 250000, China
    Recruiting
08

References and documents

Publications

  • Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18. PubMed 26095785 ↗
  • Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24. PubMed 27789196 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Jul 2019, 17 months after the start.

Of 344 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 98. This study's planned 17 months is below that.

Counting every sponsor, half of 360 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
Apr 5, 2018
StartActual
Jan 15, 2018
Primary completionEst.
Jul 1, 2019
CompletionEst.
Dec 31, 2019
Last update
Apr 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03489616
Responsible party
Jinming Yu (chief physician, Shandong Cancer Hospital and Institute) — Principal investigator
First posted
Apr 5, 2018
Start date
Jan 15, 2018
Primary completion
Jul 1, 2019 (estimated)
Completion
Dec 31, 2019 (estimated)
Last update
Apr 5, 2018

Study contacts

Ming Huan Li, doctor
Contact
sy_lmh2001@163.com
131 5303 5389
JINMING YU, doctor
Contact
jn7984729@public.jn.sd.cn
13806406293 ext. 0531-87984729
JINMING YU, doctor
principal investigator · Shandong Cancer Hospital and Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regramostim

Start the discussion